Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751869 | 0.91 | ALDH1A1 (0.43) | ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4174879 | 0.91 | ALDH1A1 (0.47) | ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3932510 | 0.91 | ALDH1A1 (0.47) | ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4189521 | 0.89 | ALDH1A1 (0.46) | ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4177944 | 0.88 | KDM4E (0.44) | ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4555820 | 0.88 | KDM4E (0.44) | ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4191981 | 0.85 | ALDH1A1 (0.52) | ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4216417 | 0.85 | SMPD1 (0.47) | ALDH1A1KDM4ECYP1A2CYP2C19LMNA | |
| SCHEMBL4754155 | 0.84 | ALDH1A1 (0.52) | ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1953789 | 0.81 | ALDH1A1 (0.46) | ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124613-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | HOSSAIN NAFIZAL | 2009-12-03 | — | — | US | disclosed |
| EP-2120935-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-7524856-B2 | Tricyclic spiroderivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| WO-2008103126-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | WO | disclosed |
| EP-1521757-B1 | TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| US-20070099945-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| EP-1699791-A1 | NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| WO-2005061499-A1 | NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | REN, TACR1, AGTR1 | ALDH1A1 1465/4885KDM4E 2276/4885CYP1A2 945/4885 |
| US-20070099945-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity | ACKR3, CXCR1, CXCR2 | ALDH1A1 707/4885KDM4E 4545/4885CYP1A2 1309/4885 |
| US-20110124613-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | GRK5, ADRB2, GRK2 | ALDH1A1 1412/4885KDM4E 2432/4885CYP1A2 1109/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | ALDH1A1 1375/4885KDM4E 2324/4885CYP1A2 888/4885 |
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | CXCR1, CXCR2, CXCR4 | ALDH1A1 946/4885KDM4E 4477/4885CYP1A2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.